Nov Current Assets
The Current Assets of Nov (NOV) as of Jun 21, 2026 is 5.82 B USD.In the previous year, Current Assets was 5.77 B USD — a change of 0.87% (higher).
Get this data via API
Financial Data API
Current Assets
5.82 BUSD
YoY
0.87%
Last updated:
Current Assets of Nov is 2026 5.82 B USD. Current Assets of Nov was 2025 5.77 B USD. It decreases by 0.87% higher compared to the previous year.
Access this data via the Eulerpool API
Nov Stock analysis
What does Nov do? Nov Inc is a globally operating company that was founded in the USA in 1976. The company specializes in the development and manufacture of products in various fields, including pharmaceuticals, biotechnology, agrochemicals, and electronics.
Nov Inc's business model is based on the research and development of new technologies and products. The company invests a significant portion of its resources in the research and development of new drugs and technologies. Nov Inc works closely with scientific organizations and universities to achieve this.
The goal of Nov Inc is to develop products that have a positive impact on health, science, and the environment. The company aims to improve the quality of life for people worldwide by developing innovative products that meet the needs of its customers.
Nov Inc is divided into several divisions. The main divisions are pharmaceuticals, biotechnology, diagnostics, crop protection, and electronics. In each of these divisions, the company produces products tailored to the needs of its customers.
In the pharmaceutical field, Nov Inc develops and produces drugs for the treatment of various diseases such as cancer, diabetes, and cardiovascular diseases. Nov Inc's products are well-known worldwide and are taken by millions of patients every day. The company is proud to make a significant contribution to improving the health of people worldwide.
In the biotechnology division, Nov Inc develops products for use in agriculture and environmental protection. This includes improved seed varieties that are more resistant to insects and diseases, thus reducing the use of pesticides. Nov Inc also produces biological pesticides that protect plants from pests while being non-toxic and environmentally friendly.
In the diagnostics division, Nov Inc develops and produces tests for the diagnosis of infectious diseases and other medical conditions. These tests are important for the timely detection of diseases and enable early treatment.
In the electronics division, Nov Inc develops and produces electronic devices and components. This includes semiconductors, sensors, and displays. These components are used in various industries, including telecommunications, automotive, and aerospace.
In addition to the above-mentioned divisions, Nov Inc also offers other products, including food additives, colorants, fragrances, and chemicals for industrial use.
Overall, Nov Inc has made a significant contribution to improving health, science, and the environment over the past decades. The company is globally recognized for its innovative products and technologies and will remain an important player in research and development in the future. Nov is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Nov stock
Current Assets of Nov amounted to 5.77 B USD 5.82 B
Access this data via the Eulerpool API
Balance Sheet — Nov
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Nov
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth